Neurology clinical trials recruiting in Pennsylvania

108 recruiting neurology trials match in Pennsylvania. Showing 20.

• A Study of Buntanetap in Participants With PDRecruiting

  Phase 2 / Phase 3 · Annovis Bio Inc. · Willow Grove, Pennsylvania

• Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle ControlRecruiting

  N/A · Jorge Gonzalez-Martinez · Pittsburgh, Pennsylvania

• Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized EldersRecruiting

  N/A · University of Michigan · Philadelphia, Pennsylvania

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRecruiting

  Phase 3 · Hoffmann-La Roche · Plymouth Meeting, Pennsylvania

• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromeRecruiting

  Phase 3 · Epygenix · Philadelphia, Pennsylvania

• Central Vein Sign in Multiple Sclerosis Extension StudyRecruiting

  N/A · The Cleveland Clinic · Cleveland, Ohio

• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting

  Phase 3 · Merck Sharp & Dohme LLC · Bethlehem, Pennsylvania

• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruiting

  Phase 3 · Eidos Therapeutics, a BridgeBio company · Philadelphia, Pennsylvania

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Recruiting

  Phase 2 · Eli Lilly and Company · Chandler, Arizona

• An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)Recruiting

  Phase 2 · Yale University · Aurora, Colorado

• Genes and Environment in Multiple SclerosisRecruiting

  N/A · Columbia University · Pittsburgh, Pennsylvania

• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic EncephalopathyRecruiting

  Phase 1 / Phase 2 · Institut de Recherches Internationales Servier · Boston, Massachusetts

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigraineRecruiting

  Phase 3 · Kallyope Inc. · Allentown, Pennsylvania

• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Recruiting

  Phase 2 · Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Recruiting

  Phase 3 · Merck Sharp & Dohme LLC · Bethlehem, Pennsylvania

• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesRecruiting

  Phase 2 · Reunion Neuroscience Inc · Philadelphia, Pennsylvania

• A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting

  Phase 1 / Phase 2 · Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Recruiting

  N/A · TG Therapeutics, Inc. · Bethlehem, Pennsylvania

• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineRecruiting

  Phase 3 · Kallyope Inc. · Allentown, Pennsylvania

• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))Recruiting

  Phase 3 · Neurona Therapeutics · Philadelphia, Pennsylvania

Source: ClinicalTrials.gov. Recruitment status changes often — confirm on each study page.